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We describe a project aimed at studying a large number of individuals (>200) with specific recurrent genetic
variations (deletion or duplication of segment 16p11.2) that increase the risk of developing autism spectrum
(ASD) and other developmental disorders. The genetics-first approach augmented by web-based recruit-
ment, multisite collaboration and calibration, and robust data-sharing policies could be adopted by other
groups studying neuropsychiatric disorders to accelerate the pace of research.Motivation for the Collection
A key need for human genetic studies, not
only in neuroscience but also in other
disease areas, is access to a large number
of individuals who have been reliably
and thoroughly characterized. Rigorous
clinical phenotyping is critical, and lack
thereof can be a major bottleneck to
progress. For many neuropsychiatric dis-
orders such as ASD, bipolar disorder,
and schizophrenia, this can be a particular
challenge given the heterogeneity and
complexity of the symptomatology for
these disorders, which are diagnosed
using inherently subjective behavioral
criteria.
For ASD, a number of initiatives have
been developed to fill this need for
well-characterized individuals and bio-
specimens. Many of these involve
consortium programs and large-scale
collaborations between multiple institutes
and investigators. Projects such as the
Autism Genetic Resource Exchange
(AGRE), which was initiated first by Cure
Autism Now and is now administered by
Autism Speaks, the Simons Simplex
Collection (SSC), the Autism Genome
Project, and the NIMH repository (Fisch-
bach and Lord, 2010; Geschwind et al.,
2001) have provided the backbone for
new discoveries in ASD genetics over
the last several years (State, 2010).
In this NeuroView, we discuss a new
initiative, the Simons VIP, which was
launched to fulfill a complementary need:
in contrast to the existing genetic collec-
tions for ASD, where recruitment ofpatients is based on clinical diagnosis,
the Simons VIP project takes a ‘‘genetics
first’’ approach. The logic behind this
approach is based on the increasing
evidence suggesting that the genetics
underlying neuropsychiatric disorders are
complex and may involve mutations in
hundreds of genes, each of which is rela-
tively infrequent. Such heterogeneity
makes it extremely challenging to perform
patient cohort studies because there may
be characteristics specific to certain sub-
sets that are not common to all individuals.
Nevertheless, certain highly penetrant
copy-number variations (CNVs) or muta-
tions in single genes are observed recur-
rently in cohorts ascertainedbypsychiatric
diagnosis. For example, in the case of ASD
seeLevyet al. (2011),Marshall et al. (2008),
and Sanders et al. (2011).
Given the relatively low recurrence (and
therefore the small number of subjects
typically studied with any specific genetic
event), it is as yet unknown whether brain
structure, neurophysiological responses,
and associated clinical phenotypes will
differ meaningfully between genetic etiol-
ogies and/or ultimately whether interven-
tions will be generalizable to all patients
or will be more effective if tailored to the
underlying genetic etiology.
By recruiting and studying large
numbersof familieswithdeletionsordupli-
cations of 16p11.2, without regard to clin-
ical diagnosis or age, we aim to address
this question by studying the cross-
sectional diversity and early longitudinal
course of this genetically well-definedNeuron 73group of individuals at the behavioral and
neurocognitive level. Although the Simons
VIP project is initially focused on 16p11.2,
the structure of the project should have
broader applications for other complex
genetic disorders. Longer-term goals are
to use these data to develop targeted
interventions and focused clinical care for
individuals with specific genetic events.
Why 16p11.2?
Of the recurrent genetic causes of neuro-
psychiatric disorders, recent work has
highlighted deletions and duplications of
a shared region on 16p11.2 as being of
particular interest given their relatively
high frequency in large clinical cytoge-
netic microarray databases (Cooper
et al., 2011; Kaminsky et al., 2011) and
the evidence implicating 16p11.2 in
a number of neuropsychiatric disorders.
An emerging theme in the field is that
the same CNV may increase risk for
multiple cognitive and neuropsychiatric
disorders. For example, the 7q11.23
deletion causes Williams Syndrome,
whereas duplication of the same region
is associated with ASD (Sanders et al.,
2011). Similarly, the chromosomal region
16p11.2 has been associated with ASD
(Weiss et al., 2008), as well as schizo-
phrenia, bipolar disorder, developmental
delay, and body weight regulation (see
Supplemental References available on-
line). Also, the specific dosage effects of
the genes in this region may regulate
components of the anthropometric
phenotype in a reciprocal fashion: early, March 22, 2012 ª2012 Elsevier Inc. 1063
Figure 1. Families Registered on Simons VIP Connect
(A) Weekly (blue) and cumulative (red) number of worldwide families registered during the first 66 weeks.
(B) Distribution of registered families in the United States (red). Study centers are indicated with blue stars.
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16p11.2 deletions may have high body
mass index (BMI) and large head circum-
ferences whereas duplications have low
BMI and small head circumferences
(Bochukova et al., 2010; Jacquemont
et al., 2011; McCarthy et al., 2009; Shi-
nawi et al., 2010; Walters et al., 2010).
The 16p11.2 CNV is 600 kb, with con-
sistent breakpoints and contains approxi-
mately 29 genes. Studying a genetic lesion
that is consistent among individuals
increases the homogeneity of the cohort
in a manner that is not usually possible for
most single-gene disorders in which a
wide variety of mutations are observed1064 Neuron 73, March 22, 2012 ª2012 Elsethat may have varying effects on function
and lead to different phenotypes associ-
ated with various genotypes.
Recruitment and Retention of
Subjects: Simons VIP Connect
Family engagement is a key factor for
success of any long-term genetic project.
For Simons VIP this begins with recruit-
ment and core phenotyping but does not
end there. For example, we have actively
engaged families with forums in which
families can learn about 16p11.2 and
interact with one another and webinars
in which families can learn about the latest
research.vier Inc.Launched inSeptember2010,SimonsVIP
Connect (http://www.simonsvipconnect.
org/) is designed to support an online
community for individuals worldwide
with 16p11.2 deletions and duplications
and their families and is the primary
means of recruiting families for the
Simons VIP. Many families find Simons
VIP Connect on their own via internet
search for 16p11.2 after they receive
results from a clinical genetic test
screening for CNVs. Our recruitment
strategies have also included directed
traffic from Google ads and Facebook
and links from other chromosomal dis-
order patient advocacy websites (Unique,
http://www.rarechromo.org, and CDO,
http://www.chromodisorder.org/CDO/).
We also established collaborations with
clinical molecular cytogenetics laborato-
ries (notably but not limited to those sites
participating in the InternationalStandards
for Cytogenomic Arrays Consortium,
[ISCA]; https://www.iscaconsortium.org/)
to notify treating physicians to refer
patients who meet study eligibility. We
also sought out referrals from medical
professionals including genetic coun-
selors, geneticists, child neurologists,
and developmental pediatricians who
were informed through direct mailings.
Families who previously participated in
the SSC who were found to have a
16p11.2 deletion or duplication were
also invited to enter the Simons VIP
study. In addition, as chromosome micro-
array testing is entering into the prenatal
area, fetuses with 16p11.2 deletions/
duplications are beginning to be identified
and provide the opportunity to understand
fetal and early childhood brain develop-
ment in this population. Within the first
year after launch, over 200 families from
around the world have joined the online
community of Simons VIP Connect. We
have registered approximately four new
families/week with a broad regional and
age distribution (Figure 1).
As much as this collection will provide
data to researchers, the project also
has a component aimed at providing
information to families. The site content
is actively curated by a team of genetic
counselors who maintain up-to-date
summaries about publications on
16p11.2, publish a newsletter for families,
and host a series of webinars by Simons
VIP scientists/physicians and outside
Figure 2. Consented and Potential Participants as of December 2011
(A) Consented individuals are in solid colors. Shaded regions indicate additional potential families for study
who are not consented because they live outside of North America or are unable to participate in the study
at the present time. While the solid bars indicate individuals, the shaded bars are numbers of families and
therefore are a conservative estimate of the number of individuals as cascade testing in registered families
often identifies additional individuals with 16p11.2 deletions (average 1.3 per family) or duplications
(average 2.1 per family).
(B) Distribution of Simons VIP participants by gender and deletion/duplication status.
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The website also offers the option to
‘‘ask an expert’’ that has been used by
patients and health care providers. Start-
ing in the summer of 2012, Simons VIP
will organize a meeting at which families
can interact directly with each other and
Simons VIP researchers. The feedback
of aggregate research results to the
patient community has been a strong
motivation to keep families engaged and
actively participating (see Supplemental
Experimental Procedures).
Inclusion in Simons VIP Study and
Ascertainment Biases
Our goal is to create a large cohort of
subjects who were as genetically similar
as possible. Below we describe steps
taken, which involve including as many
family members as possible beyond the
individual who had the original genetic
test. Also described is howwe are dealing
with ascertainment biases that compli-
cate ours and all efforts in this field.When families register for Simons VIP
Connect online (or by calling a toll-free
telephone number), they are provided
with a description of the Simons VIP study
and, if they are in the United States or
Canada, are asked if they would like
to participate. Genetic test reports are
reviewed to confirm eligibility, which con-
sists of having the canonical deletion or
duplication (600 kb, chr16: 29,557,497-
30,107,356; hg18), or a smaller CNV at
the locus. Exclusion criteria include any
other pathogenic CNVs or other neuroge-
netic or neurological diagnoses unrelated
to 16p11.2 (e.g., tuberous sclerosis).
Blood samples provided by partici-
pants are used to test for the 16p11.2
deletion/duplication by fluorescent in situ
hybridization (FISH) or comparative
genomic hybridization to determine who
in the nuclear family carries the deletion/
duplication, with cascade testing of
additional members in the family as far
as the family is willing or able to allow.
(Approximately 50% of families regis-Neuron 73tering on Simons VIP Connect already
know whether the deletion or duplication
is inherited.) All deletion/duplication
carriers in the family are eligible for partic-
ipation (see Supplemental Experimental
Procedures). Within one year, we
have obtained consent from over 100
individuals with 16p11.2 deletions or
duplications to participate in research
(Figure 2). This represents extremely effi-
cient recruitment for a rare genetic
disorder.
A limitation of our recruitment strategy
is the possible ascertainment bias to indi-
viduals who were clinically significantly
affected enough for a parent or provider
to seek an etiologic diagnosis and have
access to a clinical chromosomemicroar-
ray. This could bias the study toward
ascertainment of more severely affected
probands. By performing cascade
genetic testing within the families, we
have intentionally attempted to increase
recruitment and include individuals in
familial cases who may not have come
to clinical attention. We are also pursuing
strategies to enroll children who are
enrolled in other research studies not
targeted at developmental disabilities in
which genomic CNV analysis identified
16p11.2 deletions and duplications and
who consented to recontact. However,
given that our study is not a population-
based epidemiological study, our results
will probably only define the range of
clinical phenotypes associated with
16p11.2 deletions and duplications but
cannot be used to predict the probability
of any particular phenotype in an asymp-
tomatic fetus or infant.
Core Phenotyping and Structural
Neuroimaging
The Simons VIP represents the first
large-scale effort to study the natural
history of individuals with specific genetic
events associated with nonsyndromic
ASD and related disorders. The psycho-
logical phenotyping battery is intentionally
broad enough to capture the spectrum
of possible diagnoses of individuals
with 16p11.2 (and also appropriate for
individuals with other genetic events,
thus enabling studies that directly
compare different defined genetic condi-
tions), yet streamlined enough to allow
for completion of the protocol in a two-
day evaluation., March 22, 2012 ª2012 Elsevier Inc. 1065
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pating core phenotyping centers: Baylor
College of Medicine, Houston; Children’s
Hospital Boston, Harvard University,
Boston; or University of Washington,
Seattle. The protocol includes a com-
prehensive, age-appropriate battery of
psychological tests and interviews, a
neurological exam, growth measure-
ments, standard and three dimensional
craniofacial surface images (3dMD Inc.,
Atlanta & London) for dysmorphology,
a structural brain MRI for participants
who can complete the study without the
use of sedation, and collection of bio-
specimens including blood and an
optional skin biopsy to harvest fibroblasts
for future generation of induced pluripo-
tent stem cells (iPSCs). For a more
detailed description of the phenotyping
and imaging protocols, see Tables S1
and S2.
To avoid a common pitfall where the
same individual is reported in multiple
studies, as is often the case for rare disor-
ders, all participants are assigned a global
unique identifier (Johnson et al., 2010).
Data are entered into a custom database
designed and maintained by Prometheus
Research LLC, as previously described
(Fischbach and Lord, 2010). Bio-
specimens are processed and stored at
the Rutgers University Cell and DNA
Repository (RUCDR) for use by the
research community. Nuclear family
members who do not carry the 16p11.2
deletion/duplication are also encouraged
but not required to participate and are
evaluated with a limited number of
psychological tests to serve as controls.
These family controls serve as an impor-
tant control for other familial factors as
measures such as IQ can be compared
not only to population controls but also
the unaffected family controls.
As diagnostic differences across clin-
ical sites have often been a challenge for
human genetic studies, we have devel-
oped the phenotyping protocols with
an aim for consistency and reliability.
Diagnoses are based on standardized
measures applied to DSM-IV-TR criteria
(see Supplemental Experimental Proce-
dures). Children age 4 years and younger
will be assessed longitudinally with
a combination of parental interviews every
6 months and serial psychometric testing
at ages 6, 12, 18, 24, 36, and 48 months.1066 Neuron 73, March 22, 2012 ª2012 ElseThe structural brain MRI protocol,
which also includes sequences typically
included in a clinical scan, is identical
across sites, and the scanners are care-
fully cross-calibrated (see Supplemental
Experimental Procedures).
Functional Neuroimaging and
Neurophysiology
Many studies report signatures of brain
activity that correlate with neuropsychi-
atric disease status. Given the phenotypic
and genetic heterogeneity of these disor-
ders, including ASD, it is perhaps not
surprising that these measures are often
quite noisy, they can result in contradic-
tory results, and even the most salient
features usually require substantial
cohorts to validate. Two important
research questions are to determine
whether these signatures would be less
noisy in a more genetically homogeneous
population, and, because there is clinical
diversity within this genetically homoge-
neous cohort, whether these brain activity
signatures correlate with phenotype
(ASD) or genetic etiology (16p11.2 del/
dup). Toward this end we have added
multiple measures of brain function.
Participants who are able to complete
the structural MRI (without evidence of
significant motion artifact) and who are 7
years old or older are asked to participate
in an additional component of the study
that involves functional imaging. The
purpose of this part of the study is
to address whether detailed structural
and functional imaging coupled with
a comprehensive neuropsychological
battery on both 16p11.2 participants and
controls can identify robust correlations
between 16p11.2 deletions and duplica-
tions and brain function. The two imaging
modalities, fMRI and MEG, complement
each other with regard to tradeoffs in
temporal versus spatial resolution. The
protocols for fMRI and MEG interrogate
a broad array of cognitive domains,
including language, executive function,
and face andmotor processing and incor-
porate both resting state and task related
protocols (for more detailed imaging
protocols, see Tables S3 and S4). To
insure consistency of measures, the func-
tional imaging studies are performed over
2 days at the University of California,
San Francisco or at Children’s Hospital
of Philadelphia, where the two sites havevier Inc.nearly identical MRI and MEG hardware
and software implementations that have
been calibrated for data pooling (see
Supplemental Experimental Procedures).
Data- and Biospecimen-Sharing
Plans
A fundamental principle of this project is
that in addition to an active research
project, it is also intended to provide the
broad scientific community with a valu-
able resource for future research. Data
will be made available through a web-
based portal to approved investigators in
raw and processed forms to allow for
further analyses and comparison to other
cohorts. Researchers involved in the
creation of the Simons VIP resource
should be suitably acknowledged but
will not restrict access to the bio-
specimens, phenotype, or neuroimaging
data. Researchers can use SFARI Base
(http://base.sfari.org), the online Simons
Foundation Autism Research Initiative
(SFARI) data repository, to review specific
and aggregate characteristics, to identify
interesting subsets of cases, and to
request biospecimens and/or data in raw
and processed forms for further analyses
and comparison to other cohorts.
We believe that our data-sharing policy
is ideal in that it allows rapid access to
data and biospecimens to the community
but acknowledges that othersmaywish to
analyze or publish on their data before
releasing it to the community. As the
ability to recontact subjects can be useful
for ongoing studies, a procedure will be
in place to determine whether and when
the Simons VIP research team will recon-
tact subjects for follow-up research or
ancillary studies that require data or
biospecimens beyond those already
collected. This procedure will balance
research priorities with potential burden
on families.
Future Plans
We envision that the Simons VIP will
produce immediate information about
the medical, cognitive, and neuroimaging
profiles of subjects with deletions and
duplications of 16p11.2 that should be
of considerable value to families and
their clinicians. Phenotyping and neuroi-
maging protocols will be evaluated on
a regular basis and additions or subtrac-
tions will be made depending on the
Neuron
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may also involve recontacting families
to ask for their participation in collecting
additional data, such as EEG, quantita-
tive sleep data, or additional bio-
specimens. Furthermore, the availability
of biospecimens linked to the other
types of data will provide many future
opportunities for follow-up study. For
example, we expect that targeted rese-
quencing of the remaining or extra
16p11.2 allele and/or expression studies
may help to narrow down which genes
in the interval are of particular relevance
to the phenotypes. Exome or full-
genome sequencing of the samples
may identify other genetic alterations,
in addition to 16p11.2, that may be rele-
vant to the phenotype and differential
expressivity between individuals; anal-
ysis of epigenetics may be similarly
informative.
Studies that transform the banked
fibroblasts into iPSCs and then differen-
tiate them into neurons may help to
understand how deletions or duplications
of 16p11.2 influence early neural devel-
opment or neuronal function and may
provide an effective platform for high
throughput screening of drugs that could
potentially be tested for efficacy in this
genetically homogeneous cohort.
In addition to supporting the core
Simons VIP effort directly, SFARI will
continue to entertain proposals through
the regular Request for Applications
(RFA) for work related to the analysis of
phenotype or neuroimaging data and
specimens. SFARI is prepared to join
with other funding agencies in supporting
further studies utilizing the resources
generated by the Simons VIP effort.
In closing, the genetics-first, multisite,
and highly collaborative nature of this
project, combined with clear data-sharingpolicies, allows for ready scalability. We
think it will have broad applicability to
other efforts to understand genotype-
phenotype relationships. This approach
is especially warranted in neuropsychi-
atric disorders, where the clinical het-
erogeneity of disorders, diagnosed
behaviorally, present special problems,
but should extend beyond as well.
SUPPLEMENTAL INFORMATION
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